Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation

The role of lymphangiogenesis in inflammation has remained unclear. To investigate the role of lymphatic versus blood vasculature in chronic skin inflammation, we inhibited vascular endothelial growth factor (VEGF) receptor (VEGFR) signaling by function-blocking antibodies in the established keratin 14 (K14)–VEGF-A transgenic (Tg) mouse model of chronic cutaneous inflammation. Although treatment with an anti–VEGFR-2 antibody inhibited skin inflammation, epidermal hyperplasia, inflammatory infiltration, and angiogenesis, systemic inhibition of VEGFR-3, surprisingly, increased inflammatory edema formation and inflammatory cell accumulation despite inhibition of lymphangiogenesis. Importantly, chronic Tg delivery of the lymphangiogenic factor VEGF-C to the skin of K14-VEGF-A mice completely inhibited development of chronic skin inflammation, epidermal hyperplasia and abnormal differentiation, and accumulation of CD8 T cells. Similar results were found after Tg delivery of mouse VEGF-D that only activates VEGFR-3 but not VEGFR-2. Moreover, intracutaneous injection of recombinant VEGF-C156S, which only activates VEGFR-3, significantly reduced inflammation. Although lymphatic drainage was inhibited in chronic skin inflammation, it was enhanced by Tg VEGF-C delivery. Together, these results reveal an unanticipated active role of lymphatic vessels in controlling chronic inflammation. Stimulation of functional lymphangiogenesis via VEGFR-3, in addition to antiangiogenic therapy, might therefore serve as a novel strategy to treat chronic inflammatory disorders of the skin and possibly also other organs.

[1]  D. Carr,et al.  VEGF-A expression by HSV-1–infected cells drives corneal lymphangiogenesis , 2009, The Journal of experimental medicine.

[2]  Michael Detmar,et al.  Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis , 2009, Proceedings of the National Academy of Sciences.

[3]  E. Schwarz,et al.  Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. , 2009, Arthritis and rheumatism.

[4]  N. Ferrara.  Vascular Endothelial Growth Factor , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[5]  K. Alitalo,et al.  Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. , 2009, Blood.

[6]  R. de Waal Malefyt,et al.  Development and function of TH17 cells in health and disease. , 2009, The Journal of allergy and clinical immunology.

[7]  Pui-Yan Kwok,et al.  Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways , 2008, Nature Genetics.

[8]  H. Hvid,et al.  TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis. , 2008, International immunology.

[9]  Antonio Duarte,et al.  Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation , 2008, Nature.

[10]  M. Detmar,et al.  Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. , 2008, The American journal of pathology.

[11]  Jussi Taipale,et al.  Deletion of Vascular Endothelial Growth Factor C (VEGF-C) and VEGF-D Is Not Equivalent to VEGF Receptor 3 Deletion in Mouse Embryos , 2008, Molecular and Cellular Biology.

[12]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[13]  K. Alitalo,et al.  Molecular biology and pathology of lymphangiogenesis. , 2008, Annual review of pathology.

[14]  P. Tak,et al.  Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints , 2008, Annals of the rheumatic diseases.

[15]  K. Alitalo,et al.  Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation , 2007, Nature Medicine.

[16]  E. Schwarz,et al.  Increased lymphangiogenesis in joints of mice with inflammatory arthritis , 2007, Arthritis research & therapy.

[17]  M. Detmar,et al.  VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes. , 2007, Blood.

[18]  K. Alitalo,et al.  Molecular regulation of angiogenesis and lymphangiogenesis , 2007, Nature Reviews Molecular Cell Biology.

[19]  M. Shibuya,et al.  Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting , 2007, The Journal of experimental medicine.

[20]  M. Lebwohl,et al.  A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. , 2007, The New England journal of medicine.

[21]  S. Hirakawa,et al.  Vascular endothelial growth factor-A mediates ultraviolet B-induced impairment of lymphatic vessel function. , 2006, The American journal of pathology.

[22]  Dai Fukumura,et al.  Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. , 2006, Cancer research.

[23]  J. Bainbridge,et al.  Angiogenesis as a therapeutic target in arthritis: lessons from oncology. , 2006, Current pharmaceutical design.

[24]  A. Gasbarrini,et al.  Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. , 2006, Gastroenterology.

[25]  W. Van den Broeck,et al.  Anatomy and nomenclature of murine lymph nodes: Descriptive study and nomenclatory standardization in BALB/cAnNCrl mice. , 2006, Journal of immunological methods.

[26]  F. Ginhoux,et al.  B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. , 2006, Immunity.

[27]  S. Hirakawa,et al.  VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis , 2005, The Journal of experimental medicine.

[28]  Antonio Alcami,et al.  The chemokine receptor D6 limits the inflammatory response in vivo , 2005, Nature Immunology.

[29]  Seppo Ylä-Herttuala,et al.  Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. , 2005, The Journal of clinical investigation.

[30]  M. Skobe,et al.  Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. , 2005, Journal of the National Cancer Institute.

[31]  M. Dana,et al.  Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) on monocytic bone marrow-derived cells in the conjunctiva. , 2004, Experimental eye research.

[32]  D. Hicklin,et al.  Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. , 2004, Blood.

[33]  K. Maruyama,et al.  Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. , 2004, Investigative ophthalmology & visual science.

[34]  P. Laakkonen,et al.  Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. , 2004, Journal of the American Society of Nephrology : JASN.

[35]  Lena Claesson-Welsh,et al.  Ligand-induced Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) Heterodimerization with VEGFR-2 in Primary Lymphatic Endothelial Cells Regulates Tyrosine Phosphorylation Sites* , 2003, Journal of Biological Chemistry.

[36]  M. Dana,et al.  Novel expression of vascular endothelial growth factor receptor (VEGFR)-3 and VEGF-C on corneal dendritic cells. , 2003, The American journal of pathology.

[37]  G. Yancopoulos,et al.  Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. , 2003, Blood.

[38]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[39]  Y. Yoon,et al.  VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. , 2003, The Journal of clinical investigation.

[40]  M. Shibuya,et al.  VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice. , 2003, Biochemical and biophysical research communications.

[41]  E. Manseau,et al.  Vascular Permeability Factor/Vascular Endothelial Growth Factor Induces Lymphangiogenesis as well as Angiogenesis , 2002, The Journal of experimental medicine.

[42]  M. Skobe,et al.  Therapeutic lymphangiogenesis with human recombinant VEGF‐C , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  R. Kauppinen,et al.  A model for gene therapy of human hereditary lymphedema , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Kerjaschki,et al.  Isolation and Characterization of Dermal Lymphatic and Blood Endothelial Cells Reveal Stable and Functionally Specialized Cell Lineages , 2001, The Journal of experimental medicine.

[45]  E C Nice,et al.  Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF‐C/D receptor VEGFR‐3 , 2001, The EMBO journal.

[46]  M. Karkkainen,et al.  The Specificity of Receptor Binding by Vascular Endothelial Growth Factor-D Is Different in Mouse and Man* , 2001, The Journal of Biological Chemistry.

[47]  S. Kanazawa,et al.  VEGF, basic-FGF, and TGF-β in Crohn’s disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation , 2001 .

[48]  Seppo Ylä-Herttuala,et al.  Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3 , 2001, Nature Medicine.

[49]  K. Alitalo,et al.  VEGF‐C and VEGF‐D expression in neuroendocrine cells and their receptor, VEGFR‐3, in fenestrated blood vessels in human tissues , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  C E Griffiths,et al.  Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis , 1999, The British journal of dermatology.

[51]  K. Alitalo,et al.  VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. , 1999, The American journal of pathology.

[52]  R K Jain,et al.  Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. , 1998, The Journal of investigative dermatology.

[53]  K. Alitalo,et al.  A Recombinant Mutant Vascular Endothelial Growth Factor-C that Has Lost Vascular Endothelial Growth Factor Receptor-2 Binding, Activation, and Vascular Permeability Activities* , 1998, The Journal of Biological Chemistry.

[54]  K. Plate,et al.  Vascular endothelial growth factor , 1997, Journal of Neuro-Oncology.

[55]  Yihai Cao,et al.  Proteolytic processing regulates receptor specificity and activity of VEGF‐C , 1997, The EMBO journal.

[56]  R. Jain,et al.  Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. , 1997, Science.

[57]  K. Alitalo,et al.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[58]  H. Dvorak,et al.  Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis , 1994, The Journal of experimental medicine.

[59]  G. Haines,et al.  Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. , 1994, Journal of immunology.

[60]  N. Fusenig,et al.  Keratins of the human hair follicle: "hyperproliferative" keratins consistently expressed in outer root sheath cells in vivo and in vitro. , 1987, Differentiation; research in biological diversity.

[61]  W. Jiang,et al.  Lymphangiogenesis and cancer metastasis. , 2011, Frontiers in bioscience.

[62]  Sofie Mellberg.  Molecular Regulation of Angiogenesis , 2008 .

[63]  J. Schweizer,et al.  Keratins of the human hair follicle. , 2005, International review of cytology.

[64]  K. Alitalo,et al.  Short Communication Vascular Endothelial Growth Factor Receptor-3 in Lymphangiogenesis in Wound Healing , 2000 .